Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus

Table 2

Impact of bromocriptine-QR on a prespecified, adjudicated composite CVD endpoint, and individual components of the composite.

	Bromocriptine-QR	Placebo	Hazard ratio (95% CI)
	# subjects (%)^a	# subjects (%)^a
Intention to treat analysis
Prespecified adjudicated composite CVD endpoint (ITT)	19 (1.6)	19 (3.1)	0.52 (0.28–0.98)
Composite CVD endpoint by each component
Myocardial infarction	5 (0.4)	5 (0.8)	0.54 (0.16–1.86)
Stroke	1 (0.1)	3 (0.5)	0.18 (0.02–1.71)
Hospitalization for angina	4 (0.3)	3 (0.5)	0.71 (0.16–3.15)
Hospitalization for heart failure	3 (0.2)	4 (0.7)	0.36 (0.08–1.62)
Coronary revascularization	6 (0.5)	4 (0.7)	0.81 (0.23–2.86)
Coronary revascularization following a primary endpoint (e.g., CABG after MI)	7 (0.6)	7 (1.1)	0.53 (0.19–1.52)
On treatment analysis
Prespecified adjudicated composite CVD endpoint	15 (1.2)	18 (2.9)	0.48 (0.24–0.95)

% of events per total per group (1219 bromocriptine-QR, 615 placebo).
CI: confidence interval, CV: cardiovascular, CABG: coronary artery bypass graft, MI: myocardial infarction.